Cambridge Healthtech Institute’s 4th Annual
Oncolytic Virus Immunotherapy
Realizing the Exciting Potential of Oncolytic Virotherapy
August 6-7, 2019
Oncolytic virotherapy (OV) represents an exciting new area of cancer treatment by exploiting a virus’s ability to selectively replicate and kill tumor tissue while stimulating a patient-specific immune response against cancer. Interest in the field
is at an all-time high following significant scientific breakthroughts in mechanisms of action, efficiacy, combination therapies, delivery, and investment from big pharma players such as Pfizer, Amgen, Merck, Johnson and Johnson.
CHI’s Oncolytic Virus Immunotherapy conference brings together leading industry and academic leaders to discuss the critical steps needed to accelerate oncolytic virus immunotherapy, from delivery to combination therapy strategies; virus engineering
to manufacturing and commercialization.
Coverage will include, but is not limited to:
Improving OV Potency, Targeting and Efficacy
- Engineering strategies to improve efficacy and specificity – highly armed OVs
- What do we really know about human tumor microenvironments and how do we match OV and their armaments to tumors they will likely work in?
- New virus, mechanism of actions
- Tumor targeted delivery – latest from Ignite
- Impact of Tumor Microenvironment – vascularization
Latest updates and Future Directions in Oncolytic Virus Immunotherapy
- Update on recent deals, science and collaborations – what are the market dynamics – types of viruses (Herpes, Adeno, Vaccinia)
- Feedback from big pharma, Pfizer, Amgen’s post T-Vec OV portfolio
- What needs to happen to take OVs forward
- Update from companies with late-stage products/approvals – post market approvals
Oncolytics in an Era of Combination Therapies
- Are combinations the only way forward for oncolytics?
- Examples of successful combination models – checkpoints, CAR Ts, kinase inhibitors, alternative to checkpoints, antibodies
- What is the relevance of syngeneic mouse tumor models for identifying good OV and combination regimens?
- Potential and pitfalls of humanized mouse models for testing human optimized OV
- Issues when combining OVs – feedback on trials
- Evidence to support role of oncolytics as monotherapies?
Improving Delivery and Administration
- Oncolytics as a single shot vs. multiple shots – mechanisms of action. Evidence-based medicine.
- IV vs. systemic - dosage, delivery, delivery when combining with PD-1s
- Evidence to support systemic route, what data is available
Oncolytics in Development: Update on Major Clinical and Preclinical Therapies
- Clinical updates – results, safety, efficacy issues, patient selection, setting endpoints, presenting data to physicians
- Lessons learnt in the clinic – translational strategies, novel preclinical model biomarkers
- Regulatory expectations – what to submit to regulators, data to include, feedback
If you would like to submit a proposal to give a presentation at this meeting, please click here.
The deadline for priority consideration is January 11, 2019.
All proposals are subject to review by session chairmen and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
For more details on the conference, please contact:
Senior Conference Director
Cambridge Healthtech Institute
Phone: (+1) 781-247-6266
For partnering and sponsorship information, please contact:
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286